Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Aridis Pharmaceuticals stock price, quote, forecast and news

ARDS
US0403341045
A2N38H

Price

0.00
Today +/-
+0
Today %
+0 %
P

Aridis Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Aridis Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Aridis Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Aridis Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Aridis Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Aridis Pharmaceuticals Stock Price History

DateAridis Pharmaceuticals Price
9/5/20240.00 undefined
8/28/20240.00 undefined
8/23/20240.00 undefined
8/20/20240.00 undefined
8/19/20240.00 undefined
8/13/20240.00 undefined
8/12/20240.00 undefined

Aridis Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aridis Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aridis Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aridis Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aridis Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aridis Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aridis Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aridis Pharmaceuticals’s growth potential.

Aridis Pharmaceuticals Revenue, EBIT and net profit per share

DateAridis Pharmaceuticals RevenueAridis Pharmaceuticals EBITAridis Pharmaceuticals Net Income
2028e257.63 M undefined0 undefined0 undefined
2027e201.47 M undefined164.59 M undefined0 undefined
2026e132.77 M undefined96.61 M undefined4.4 M undefined
2025e77.44 M undefined40.38 M undefined66.83 M undefined
2024e7.75 M undefined-4.39 M undefined-4.09 M undefined
2023e21.83 M undefined5.71 M undefined3.18 M undefined
20223.09 M undefined-29.99 M undefined-30.37 M undefined
20211.54 M undefined-42.71 M undefined-46.32 M undefined
20201 M undefined-22.4 M undefined-22.33 M undefined
20191.02 M undefined-29.09 M undefined-29.68 M undefined
20182.76 M undefined-24.12 M undefined-23.46 M undefined
2017860,000 undefined-19.74 M undefined-27.45 M undefined
20162.27 M undefined-7.88 M undefined-8.89 M undefined
20152.86 M undefined-7.91 M undefined-8.2 M undefined

Aridis Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201520162017201820192020202120222023e2024e2025e2026e2027e2028e
2202111321777132201257
-----50.00--200.00600.00-66.671,000.0071.4352.2727.86
--------733.33------
0000000-22000000
-7-7-19-24-29-22-42-295-440961640
-350.00-350.00--1,200.00-2,900.00-2,200.00-4,200.00-966.6723.81-57.1451.9572.7381.59-
-8-8-27-23-29-22-46-303-466400
--237.50-14.8126.09-24.14109.09-34.78-110.00-233.33-1,750.00-93.94--
7.897.897.898.118.469.1712.2918.78000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Aridis Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Aridis Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20152016201720182019202020212022
               
2.8922.2925.124.2420.98.2318.14.88
0.520.0701.660001
000041000240
00000000
0.150.050.242.454.534.156.065.51
3.5622.4125.3428.3525.8412.3824.1611.63
0.040.040.751.271.011.261.362.15
00096010000
00005309010078
5050404030302017
00000000
220403501,000560990930827
0.310.131.143.272.142.372.413.07
3.8722.5426.4831.6227.9814.7526.5714.7
               
25.9158.974.200000
-16.64-24.95-15.1497.4104.4114.42152.18166.38
-11.29-20.18-47.63-71.09-100.77-123.1-165.3-195.67
00000005.05
00000000
-2.0213.7711.4326.313.63-8.68-13.12-24.23
0.40.680.932.331.761.895.246.09
1.681.722.122.942.971.336.4610.1
0.1500.120.0214.618.7920.9520.19
3.680000000
00000440700519
5.912.43.175.2919.3322.4533.3536.9
000000.285.280
00000000
06.3711.87051.081.282.03
06.3711.87051.366.562.03
5.918.7715.045.2924.3323.8139.9138.93
3.8922.5426.4731.627.9615.1326.7914.69
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Aridis Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Aridis Pharmaceuticals's financial health and stability.

Assets

Aridis Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Aridis Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Aridis Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Aridis Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20152016201720182019202020212022
-8-8-24-22-29-22-42-30
00000000
00000000
000-218010-1
21602282
00000000
00000000
-4-6-17-24-8-20-22-29
00000000
000-10000
000-10000
00000000
30000055
0252125472912
3252125483414
--------2.00
00000000
01920-3-1211-14
-4.49-6.11-18.26-24.95-8.33-20.85-23.47-29.21
00000000

Aridis Pharmaceuticals stock margins

The Aridis Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aridis Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aridis Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aridis Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aridis Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aridis Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aridis Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aridis Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aridis Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aridis Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aridis Pharmaceuticals Margin History

Aridis Pharmaceuticals Gross marginAridis Pharmaceuticals Profit marginAridis Pharmaceuticals EBIT marginAridis Pharmaceuticals Profit margin
2028e-731.15 %0 %0 %
2027e-731.15 %81.69 %0 %
2026e-731.15 %72.76 %3.32 %
2025e-731.15 %52.14 %86.3 %
2024e-731.15 %-56.58 %-52.78 %
2023e-731.15 %26.17 %14.58 %
2022-731.15 %-970.33 %-982.56 %
2021-731.15 %-2,773.38 %-3,007.79 %
2020-731.15 %-2,240 %-2,233 %
2019-731.15 %-2,851.96 %-2,909.8 %
2018-731.15 %-873.91 %-850 %
2017100 %-2,295.35 %-3,191.86 %
201614.98 %-347.14 %-391.63 %
201524.83 %-276.57 %-286.71 %

Aridis Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Aridis Pharmaceuticals earnings per share therefore indicates how much revenue Aridis Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aridis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aridis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aridis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aridis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Aridis Pharmaceuticals Revenue, EBIT and net profit per share

DateAridis Pharmaceuticals Sales per ShareAridis Pharmaceuticals EBIT per shareAridis Pharmaceuticals Earnings per Share
2028e5.78 undefined0 undefined0 undefined
2027e4.52 undefined0 undefined0 undefined
2026e2.98 undefined0 undefined0.1 undefined
2025e1.74 undefined0 undefined1.5 undefined
2024e0.17 undefined0 undefined-0.09 undefined
2023e0.49 undefined0 undefined0.07 undefined
20220.16 undefined-1.6 undefined-1.62 undefined
20210.13 undefined-3.48 undefined-3.77 undefined
20200.11 undefined-2.44 undefined-2.44 undefined
20190.12 undefined-3.44 undefined-3.51 undefined
20180.34 undefined-2.97 undefined-2.89 undefined
20170.11 undefined-2.5 undefined-3.48 undefined
20160.29 undefined-1 undefined-1.13 undefined
20150.36 undefined-1 undefined-1.04 undefined

Aridis Pharmaceuticals business model

Aridis Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development of immunotherapeutics and antibiotics for the treatment of infectious diseases. It was founded in 2003 in San Jose, California. The company's business model aims to address the gap in the infectious disease market caused by antibiotic resistance and the lack of new therapy options. Aridis has developed several patented technologies that allow for the quick and effective identification of potential candidates for new therapies. The company focuses on antibiotic development, utilizing a library of human monoclonal antibodies targeted specifically for infectious diseases. These antibodies can be used to target bacteria and achieve better efficacy against antibiotic resistance. Aridis has promising candidates in clinical development. The company also focuses on the development of immunotherapeutics for infectious diseases. They have developed a portfolio of monoclonal antibodies that target pathogenic microbes and can activate immune cells to strengthen the body's immune system. Some of Aridis' key products include Aerucin for the treatment of pneumonia and other respiratory diseases, and AR-101 for severe infections caused by Pseudomonas aeruginosa. Both products are currently in Phase II of development. Another important product is AR-301, a monoclonal antibody developed for the treatment of severe Staphylococcus infections. AR-301 has successfully completed Phase IIb studies and is currently undergoing accelerated approval by the US Food and Drug Administration (FDA). Aridis has formed collaborations with academic institutions and other biopharmaceutical companies to access the latest scientific knowledge and technologies. They have partnerships with multiple universities and research institutes worldwide. The company has also partnered with AmpliPhi Biosciences for the development of bacteriophage-based therapies for infectious diseases, and with Mount Sinai Health System for the development of immunotherapeutics for respiratory diseases. Overall, Aridis has a strong position in the infectious disease market and is well-positioned to address the gap caused by antibiotic resistance and the lack of new therapies. With a strong portfolio of patented technologies, promising candidates in clinical development, and broad partnerships, the company has the potential to become a leading player in the industry. Aridis Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Aridis Pharmaceuticals SWOT Analysis

Strengths

Aridis Pharmaceuticals Inc has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong Product Pipeline: Aridis Pharmaceuticals Inc has a robust pipeline of novel, potential life-saving anti-infective therapies, which provides a competitive edge in addressing unmet medical needs.
  • Innovative Technologies: The company utilizes cutting-edge technologies such as fully human monoclonal antibodies and iron-acquisition strategies for developing its therapeutic candidates, positioning itself as a leader in the industry.
  • Strategic Partnerships: Aridis Pharmaceuticals Inc has established strategic partnerships with leading pharmaceutical companies, enabling access to necessary resources, expertise, and potential market opportunities.
  • Experienced Management Team: The company is led by a highly experienced management team with a successful track record in drug development and commercialization, ensuring effective decision-making and execution of strategies.

Despite its strengths, Aridis Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and competitive position. These weaknesses include:

  • Dependency on Partnerships: The company's reliance on strategic partnerships for resources and market access may pose risks in terms of potential conflicts of interest or limitations in decision-making autonomy.
  • Limited Product Portfolio: Aridis Pharmaceuticals Inc currently has a limited number of drugs in its portfolio, which may impact revenue generation and increase vulnerability to market-related fluctuations.
  • Regulatory Challenges: The pharmaceutical industry is highly regulated, and any delays or difficulties in obtaining regulatory approvals could significantly impact the company's ability to bring its products to market in a timely manner.
  • Financial Constraints: The company's financial resources may be limited, potentially hindering the ability to fully develop and commercialize its pipeline products or invest in new research and development initiatives.

Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:

  • Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
  • Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
  • Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
  • Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.

Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:

  • Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
  • Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
  • Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
  • Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.

Weaknesses

Despite its strengths, Aridis Pharmaceuticals Inc also faces certain weaknesses that could hinder its growth and competitive position. These weaknesses include:

  • Dependency on Partnerships: The company's reliance on strategic partnerships for resources and market access may pose risks in terms of potential conflicts of interest or limitations in decision-making autonomy.
  • Limited Product Portfolio: Aridis Pharmaceuticals Inc currently has a limited number of drugs in its portfolio, which may impact revenue generation and increase vulnerability to market-related fluctuations.
  • Regulatory Challenges: The pharmaceutical industry is highly regulated, and any delays or difficulties in obtaining regulatory approvals could significantly impact the company's ability to bring its products to market in a timely manner.
  • Financial Constraints: The company's financial resources may be limited, potentially hindering the ability to fully develop and commercialize its pipeline products or invest in new research and development initiatives.

Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:

  • Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
  • Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
  • Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
  • Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.

Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:

  • Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
  • Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
  • Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
  • Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.

Opportunities

Aridis Pharmaceuticals Inc can capitalize on several opportunities within the pharmaceutical sector to drive its growth and enhance its competitive position. These opportunities include:

  • Increasing Demand for Anti-Infective Therapies: Given the rise in antibiotic resistance and the ongoing global health challenges, there is a growing demand for innovative anti-infective therapies, creating a significant market opportunity for the company.
  • Emerging Markets: The company can expand its market presence into emerging economies where there is increasing healthcare spending and a rising prevalence of infectious diseases, offering potential for revenue growth.
  • Strategic Collaborations: Aridis Pharmaceuticals Inc can explore additional collaborations with leading academic institutions, research organizations, or pharmaceutical companies to leverage their expertise, access new technologies, and strengthen its product pipeline.
  • Government Support: The company may benefit from government initiatives, grants, or tax incentives aimed at the development of novel therapies or addressing public health concerns.

Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:

  • Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
  • Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
  • Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
  • Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.

Threats

Aridis Pharmaceuticals Inc also faces certain threats that could potentially impact its business operations and market position. These threats include:

  • Competitive Landscape: The pharmaceutical industry is highly competitive, with numerous well-established companies and emerging biotech firms. This competition poses a challenge in terms of market share acquisition and potential pricing pressures.
  • Intellectual Property Protection: Protecting intellectual property rights is crucial in the pharmaceutical industry. Any infringement or challenges to the company's patents or proprietary technology could impact its ability to monetize its innovations or maintain a competitive edge.
  • Clinical Trial Risks: The success of Aridis Pharmaceuticals Inc's pipeline products relies on the outcome of clinical trials. Unforeseen complications, ineffective results, or delays in trial completion can significantly impact the timeline and success of product commercialization.
  • Regulatory and Compliance Changes: The pharmaceutical industry is subject to evolving regulations and compliance requirements. Changes in governmental policies or safety regulations may increase costs, cause delays, or impose additional burdens on the company's operations.

Aridis Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Aridis Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Aridis Pharmaceuticals shares outstanding

The number of shares was Aridis Pharmaceuticals in 2023 — This indicates how many shares 18.777 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Aridis Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Aridis Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Aridis Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Aridis Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Aridis Pharmaceuticals.

Aridis Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.1 0  (100 %)2023 Q3
12/31/2022-0.42 -0.6  (-43.47 %)2022 Q4
9/30/2022-0.17 -0.47  (-171.05 %)2022 Q3
6/30/2022-0.06 -0.45  (-635.29 %)2022 Q2
3/31/2022-0.52 -0.44  (15.42 %)2022 Q1
12/31/2021-0.42 -0.92  (-119.99 %)2021 Q4
9/30/2021-0.52 -1.94  (-270.51 %)2021 Q3
6/30/2021-0.64 -0.55  (14.08 %)2021 Q2
3/31/2021-0.63 -0.77  (-22.24 %)2021 Q1
12/31/2020-0.61 -0.59  (2.51 %)2020 Q4
1
2

Aridis Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
11.59689 % Cystic Fibrosis Foundation5,168,732011/2/2023
10.37961 % Armistice Capital LLC4,626,1904,626,19012/31/2023
1.65437 % Truong (Vu)737,353011/2/2023
1.57535 % Patzer (Eric)702,13240011/2/2023
1.00199 % Roumell Asset Management, L.L.C.446,588446,5883/31/2024
0.01144 % Jafri (Hasan)5,100011/2/2023
0.00449 % Hamilton (John F)2,000-54,70811/2/2023
0.00034 % Bartlett Wealth Management15015012/31/2023
0 % Windham-Bannister (Susan Richards)0-38,98711/2/2023
0 % Cornerstone Wealth Management, LLC0-20,0009/30/2023
1
2
3
4
...
5

Aridis Pharmaceuticals Executives and Management Board

Dr. Vu Truong59
Aridis Pharmaceuticals Chief Executive Officer, Co-Founder, Chief Scientific Officer, Director (since 2003)
Compensation 660,150
Dr. Hasan Jafri56
Aridis Pharmaceuticals Chief Medical Officer
Compensation 586,774
Dr. Eric Patzer
Aridis Pharmaceuticals Co-Founder, Executive Chairman of the Board (since 2003)
Compensation 262,800
Mr. John Hamilton78
Aridis Pharmaceuticals Independent Director
Compensation 40,500
Dr. Susan Windham- Bannister73
Aridis Pharmaceuticals Independent Director
Compensation 37,500
1
2

Aridis Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Shenzhen Hepalink Pharmaceutical Group H Stock
Shenzhen Hepalink Pharmaceutical Group H
SupplierCustomer0,11-0,560,300,690,89-
Emergent BioSolutions Stock
Emergent BioSolutions
SupplierCustomer0,010,470,870,630,830,85
1

Most common questions regarding Aridis Pharmaceuticals

What values and corporate philosophy does Aridis Pharmaceuticals represent?

Aridis Pharmaceuticals Inc represents values of innovation, dedication, and commitment to improving global health. The company's corporate philosophy revolves around developing targeted and effective immunotherapies for infectious diseases. Aridis Pharmaceuticals Inc is focused on pioneering the development of novel monoclonal antibodies and antiviral therapeutics to combat various pathogens. With a strong emphasis on research and development, Aridis strives to bring groundbreaking treatments to market, addressing critical unmet medical needs. By leveraging advanced technologies and strategic collaborations, Aridis Pharmaceuticals Inc aims to make a positive impact on society by providing life-saving solutions for infectious diseases.

In which countries and regions is Aridis Pharmaceuticals primarily present?

Aridis Pharmaceuticals Inc primarily operates in the United States, focusing on the development and commercialization of innovative anti-infective therapies. With its headquarters in San Jose, California, the company leverages its proprietary technologies to address global infectious diseases. Aridis Pharmaceuticals Inc's presence extends beyond regional bounds, as it collaborates with international partners, conducts clinical trials, and explores potential expansion opportunities. Expanding its reach and impact, Aridis Pharmaceuticals Inc remains committed to delivering breakthrough treatments worldwide, combating infectious diseases and improving patient outcomes.

What significant milestones has the company Aridis Pharmaceuticals achieved?

Aridis Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully completed a Phase 1 clinical trial for its lead candidate, AR-301, a potential treatment for severe pneumonia caused by bacterial infections. Aridis also entered into a licensing agreement with Bharat Biotech to develop a vaccine for COVID-19. Furthermore, the company received a grant from the National Institutes of Health to support the development of AR-201, a potential treatment for hospital-acquired pneumonia. These achievements demonstrate Aridis Pharmaceuticals Inc's commitment to advancing innovative therapies for infectious diseases and its potential to make a significant impact in the healthcare industry.

What is the history and background of the company Aridis Pharmaceuticals?

Aridis Pharmaceuticals Inc, founded in 2003, is a biopharmaceutical company based in San Jose, California. Specializing in the discovery and development of targeted immunotherapies to treat infectious diseases, Aridis Pharmaceuticals has made significant advancements in combating severe infections. The company has a robust pipeline of novel therapies, utilizing its proprietary technologies such as Monoclonal Antibody AR-301, designed to neutralize bacterial toxins associated with severe pneumonia. Aridis Pharmaceuticals focuses on improving patient outcomes and reducing healthcare costs through the development of highly effective and safe immunotherapies. With a commitment to innovation, Aridis Pharmaceuticals is at the forefront of addressing unmet medical needs in the field of infectious diseases.

Who are the main competitors of Aridis Pharmaceuticals in the market?

The main competitors of Aridis Pharmaceuticals Inc in the market include companies like Johnson & Johnson, Pfizer Inc, Moderna Inc, GlaxoSmithKline plc, and AstraZeneca plc.

In which industries is Aridis Pharmaceuticals primarily active?

Aridis Pharmaceuticals Inc primarily operates in the biotechnology and pharmaceutical industries.

What is the business model of Aridis Pharmaceuticals?

Aridis Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative anti-infective therapies. The company focuses on utilizing its proprietary technology platforms to create monoclonal antibodies that can effectively target and neutralize infectious pathogens. By harnessing the power of the immune system, Aridis Pharmaceuticals aims to provide solutions for combating a wide range of infectious diseases, including bacterial, fungal, and viral infections. Through strategic partnerships and collaborations, the company aims to accelerate the development and commercialization of its product candidates, bringing much-needed therapeutic options to patients worldwide.

What is the P/E ratio of Aridis Pharmaceuticals 2024?

The Aridis Pharmaceuticals P/E ratio is -0.

What is the P/S ratio of Aridis Pharmaceuticals 2024?

The Aridis Pharmaceuticals P/S ratio is 0.

What is the AlleAktien quality score of Aridis Pharmaceuticals?

The AlleAktien quality score for Aridis Pharmaceuticals is 5/10.

What is the revenue of Aridis Pharmaceuticals 2024?

The expected Aridis Pharmaceuticals revenue is 7.75 M USD.

How high is the profit of Aridis Pharmaceuticals 2024?

The expected Aridis Pharmaceuticals profit is -4.09 M USD.

What is the business model of Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of infectious diseases. The company's business model is based on several areas, including research and development, production, and distribution. Aridis focuses on the discovery and development of novel immunotherapies, particularly monoclonal antibodies and immunomodulators that specifically target the underlying pathomechanisms of infectious diseases. The company has an extensive pipeline of product candidates targeting various bacterial and viral infections. Aridis also places importance on quality and efficient processes in its production facilities. The company collaborates closely with leading pharmaceutical companies and distribution partners for international marketing and distribution. In addition to infectious diseases, Aridis aims to expand its technology and expertise in immunology to other areas such as cancer immunotherapies and autoimmune diseases. The company works with academic institutions and government agencies to enhance its research efforts and accelerate the development of novel immunotherapies. Overall, Aridis' business model is based on the development and commercialization of innovative immunotherapies for infectious diseases, with a strong focus on research and development, efficient production, and collaborations with partners.

What is the Aridis Pharmaceuticals dividend?

Aridis Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Aridis Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Aridis Pharmaceuticals or the company does not pay out a dividend.

What is the Aridis Pharmaceuticals ISIN?

The ISIN of Aridis Pharmaceuticals is US0403341045.

What is the Aridis Pharmaceuticals WKN?

The WKN of Aridis Pharmaceuticals is A2N38H.

What is the Aridis Pharmaceuticals ticker?

The ticker of Aridis Pharmaceuticals is ARDS.

How much dividend does Aridis Pharmaceuticals pay?

Over the past 12 months, Aridis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aridis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aridis Pharmaceuticals?

The current dividend yield of Aridis Pharmaceuticals is .

When does Aridis Pharmaceuticals pay dividends?

Aridis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aridis Pharmaceuticals?

Aridis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aridis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aridis Pharmaceuticals located?

Aridis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aridis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aridis Pharmaceuticals from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Aridis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Aridis Pharmaceuticals in the year 2023?

In the year 2023, Aridis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aridis Pharmaceuticals pay out the dividend?

The dividends of Aridis Pharmaceuticals are distributed in USD.

All fundamentals about Aridis Pharmaceuticals

Our stock analysis for Aridis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aridis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.